The main mechanism of action of sulfonylurea hypoglycemic agents, including glibenclamide, glipizide, gliclazide, glipizide and glimepiride, is to stimulate insulin secretion from pancreatic B cells. The hypoglycemic effect of sulfonylureas presupposes that the body still preserves a certain number of functional pancreatic B cells, and is mostly used in the treatment of newly diagnosed non-obese patients with type 2 diabetes, which can be combined with other oral hypoglycemic drugs with different mechanisms of action or insulin. However, it cannot be used in patients with type 1 diabetes and type 2 diabetes with poor islet function, nor can it be used in children with diabetes, pregnant women, or lactating women. Common adverse reactions are hypoglycemic reactions, in which glipizide is excreted from the kidney at a low rate of only 5%, while it can be applied optionally in mild and moderate renal insufficiency, but glipizide should not be used in severe renal hypofunction as well.